Innate Pharma S.A. (FRA:IDDA)
Germany · Delayed Price · Currency is EUR 1.490
-0.010 (-0.67%)
Jan 16, 2026, 4:00 PM EST
Innate Pharma Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 6 | 12.62 | 51.9 | 49.58 | 12.11 | 56.16 |
Other Revenue | 6.64 | 7.5 | 9.74 | 8.09 | 12.59 | 13.62 |
| 12.64 | 20.12 | 61.64 | 57.67 | 24.7 | 69.77 | |
Revenue Growth (YoY) | -62.60% | -67.36% | 6.88% | 133.47% | -64.59% | -18.34% |
Cost of Revenue | 43.42 | 51.98 | 56.02 | 51.66 | 47 | 49.71 |
Gross Profit | -30.79 | -31.86 | 5.62 | 6.01 | -22.3 | 20.07 |
Selling, General & Admin | 19.9 | 19.72 | 18.29 | 22.44 | 25.52 | 18.99 |
Operating Expenses | 19.9 | 19.72 | 18.29 | 22.44 | 25.52 | 18.99 |
Operating Income | -50.69 | -51.58 | -12.67 | -16.43 | -47.83 | 1.08 |
Interest Expense | -0.5 | -0.57 | -0.64 | -0.29 | -0.31 | -0.34 |
Interest & Investment Income | 1.96 | 2.44 | 3.18 | 0.55 | 0.33 | 0.56 |
Currency Exchange Gain (Loss) | 2.2 | -1.75 | 0.91 | 0.83 | 1.25 | -1.58 |
Other Non Operating Income (Expenses) | 0.98 | 1.98 | 1.65 | -1.63 | 1.08 | -0.55 |
EBT Excluding Unusual Items | -46.05 | -49.47 | -7.57 | -16.97 | -45.48 | -0.83 |
Asset Writedown | - | - | - | -41 | - | - |
Pretax Income | -46.05 | -49.47 | -7.57 | -57.97 | -45.48 | -0.83 |
Earnings From Continuing Operations | -46.05 | -49.47 | -7.57 | -57.97 | -45.48 | -0.83 |
Earnings From Discontinued Operations | - | - | - | -0.13 | -7.33 | -63.16 |
Net Income | -46.05 | -49.47 | -7.57 | -58.1 | -52.81 | -63.98 |
Net Income to Common | -46.05 | -49.47 | -7.57 | -58.1 | -52.81 | -63.98 |
Shares Outstanding (Basic) | 84 | 81 | 80 | 80 | 80 | 79 |
Shares Outstanding (Diluted) | 84 | 81 | 80 | 80 | 80 | 79 |
Shares Change (YoY) | 4.15% | 0.74% | 1.02% | 0.12% | 0.77% | 17.97% |
EPS (Basic) | -0.55 | -0.61 | -0.09 | -0.73 | -0.66 | -0.81 |
EPS (Diluted) | -0.55 | -0.61 | -0.09 | -0.73 | -0.66 | -0.81 |
Free Cash Flow | -41.26 | -7.29 | -32.91 | -19.69 | -59.39 | -52.67 |
Free Cash Flow Per Share | -0.49 | -0.09 | -0.41 | -0.25 | -0.75 | -0.67 |
Gross Margin | -243.65% | -158.34% | 9.12% | 10.42% | -90.28% | 28.76% |
Operating Margin | -401.15% | -256.32% | -20.55% | -28.48% | -193.60% | 1.55% |
Profit Margin | -364.44% | -245.87% | -12.28% | -100.74% | -213.78% | -91.70% |
Free Cash Flow Margin | -326.54% | -36.22% | -53.39% | -34.14% | -240.40% | -75.49% |
EBITDA | -49.77 | -50.27 | -8.53 | -12.02 | -43.23 | 13.31 |
EBITDA Margin | - | -249.86% | -13.84% | -20.84% | -174.99% | 19.07% |
D&A For EBITDA | 0.92 | 1.3 | 4.14 | 4.41 | 4.6 | 12.23 |
EBIT | -50.69 | -51.58 | -12.67 | -16.43 | -47.83 | 1.08 |
EBIT Margin | - | -256.32% | -20.55% | -28.48% | -193.60% | 1.55% |
Revenue as Reported | 12.64 | 20.12 | 61.64 | 57.67 | 24.7 | 69.77 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.